ADVANCED MEDICAL PRODUCTS INC
SC 13D, 2000-03-28
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: ADVANCED MEDICAL PRODUCTS INC, SC 13D, 2000-03-28
Next: IDS MANAGED FUTURES L P, 10-K, 2000-03-28



                         	SECURITIES AND EXCHANGE COMMISSION
	                              WASHINGTON, D.C.   20549

                                   	SCHEDULE 13D

                      	Under the Securities Exchange Act of 1934



                             	ADVA INTERNATIONAL INC.
                               	(Name of Issuer)


                          	Common Stock - $.001 Par Value
	                          (Title of Class of Securities)



                                  	00100W-10-8
	                                (CUSIP Number)



                                 	L. John Ankney
	                               6 Woodcross Drive
	                        Columbia, South Carolina 29212
	                                (803) 407-3044
	                 (Name, Address and Telephone Number of Person
	                 Authorized to Receive Notices and Communications)


                                 	March 24, 2000
	             (Date of Event Which Requires Filing of this Statement)



If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4),
check the following box [  ].



1.	NAME OF REPORTING PERSONS
   S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

         L. John Ankney		[313 24 4616]

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)	[   ]
                                                    (b)	[   ]

3.	SEC USE ONLY


4.	SOURCE OF FUNDS

         00

5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
   IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)				[   ]

6.	CITIZENSHIP OR PLACE OF ORGANIZATION

         U.S.A, South Carolina

7.	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

         SOLE VOTING POWER

          10,000

8.	SHARED VOTING POWER

         330,000

9.	SOLE DISPOSITIVE POWER

          10,000

10.	SHARED DISPOSITIVE POWER

         330,000

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        340,000

12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
    EXCLUDES CERTAIN SHARES							[   ]

13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

        51.8%

14.	TYPE OF REPORTING PERSON

        Director

Item 1.  	Security and Issuer.

This Schedule 13D is filed on behalf of L John Ankney (the "Reporting
Person"), relative to the $ .001 par value Common Stock issued by ADVA
International Inc.  The principal executive offices of ADVA International Inc.
are located at 6 Woodcross Drive, Columbia, South Carolina 29212.

Item 2.	Identity and Background.

Reporting Person

(a)	L. John Ankney;
(b)	6 Woodcross Drive, Columbia, South Carolina 29212;
(c)	The principal occupation of the Reporting Person is a Director of
    BIOTEL Inc., in the BIOTEL Inc. principal executive offices located
    at 6 Woodcross Drive, Columbia, South Carolina 29212.  BIOTEL Inc.
    is a holding company that owns stock in several companies, including
    ADVA International Inc.,
(d) and (e)   See below;
(f)	United States citizen.

During the last five years, the above (i) has not been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors), and
(ii) was not party to a civil proceeding of a judicial or administrative body
or of competent jurisdiction and as a result of such proceeding, was not or is
not subject to a judgment, decree or final order enjoining future violations of,
or prohibiting or mandating activities subject to, Federal or State securities
laws or finding any violation or respect to such laws.

Item 3.	Source and Amount of Funds or Other Consideration.

The Reporting Person acquired 10,000 shares of Common Stock of ADVA
International Inc. (the "Shares") on March 24, 2000, issued as stock in lieu of
cash compensation for consulting services under the 2000 CONSULTING PLAN, which
is filed herein by reference as Exhibit A. Prior to March 24, 2000, the
Reporting Person did not own directly any shares of ADVA International Inc. but
because of his position as a Director of BIOTEL Inc., he is deemed to be a
beneficial owner of and have shared voting power with regard to the 330,000
shares of ADVA International Inc. owned by BIOTEL Inc.

Item 4.	Purpose of the Transaction.

	The Shares were issued as stock in lieu of cash compensation for
consulting services consisting of providing advice and counsel regarding ADVA
International Inc. Board's decision that it is in the best interest of all of
the stockholders of ADVA International Inc. to pursue opportunities to merge a
private company into ADVA International Inc., a Bulletin Board traded public
shell.  Consulting services will also include negotiating a suitable
transaction with interested parties, and recommending certain changes in the
corporate structure to accommodate such a "reverse merger" or "share
exchange".   The Reporting Person, along with others appointed by the Board of
ADVA International Inc., shall act as a "Committee" appointed for the purpose
of seeking potential reverse merger or share exchange candidates, or
technology or business partners, reviewing available information, negotiating
terms of a share exchange or merger, or terms of a stock sale, and presenting
recommendations to the Board of ADVA International Inc. for approval; in
addition, the committee may seek opportunities and pursue negotiations with
potential alliances and partners, merger/acquisition candidates, joint
ventures, corporate partners, technology partners, and others, excluding
financial and financially related transactions and any activities related to
capital formation.

	ADVA International Inc. has been advised that BIOTEL, Inc. has had
discussions with several parties regarding the possibility of BIOTEL selling
its 3,300,000 common stock shares of the Company, and intends to vote its
majority shares in the Company in favor of a reverse merger or a share exchange
if a suitable candidate can be obtained.  No agreement has been reached with
any party at this time. All of the current Directors of ADVA International Inc.
have agreed to resign if their resignation is requested in order to facilitate
a possible share exchange or reverse merger that could create value for the
Company's stockholders.

Except as described in this Schedule 13D, including this Item 4, the
Reporting Person has no plans or proposals which relate to or which would
result in any events described in subsections (a) through (j) of Item 4 of
the General Instructions to Schedule 13D.

Item 5.	Interest in Securities of the Issuer.

(a) As of March 24, 2000, the Reporting Person beneficially owned
    340,000 shares (or approximately 51.8% of the outstanding shares) of
    ADVA International Inc.
(b) The Reporting Person will have sole power to vote and to dispose of
    the 10,000 shares.
(c)	As of March 24, 2000, and within the last 60 days, to the best
    knowledge and belief of the undersigned, other than as described
    herein, no transactions involving ADVA International Inc. equity
    securities had been engaged in by the Reporting Person.
(d)	No other person is known to have the right to receive or the power
    to direct the receipt of dividends from, or the proceeds from the
    sale of the Shares.

Item 6. 	Contracts, Arrangements, Understandings or Relationships with Respect
         to Securities of the Issuer.

		None.

Item 7.	Material to be Filed as Exhibits.

1.	Filed herein by Reference as Exhibit A, the 2000 CONSULTING PLAN
filed with the Securities and Exchange Commission on March 6, 2000 by ADVA
International Inc. as Exhibit 99 to Form S-8 dated March 6, 2000.

After reasonable inquiry and to the best knowledge and belief of the
undersigned, it is hereby certified that the information set forth in this
statement is true, complete and correct.



Dated:  March 28, 2000

  /s/L. JOHN ANKNEY

     L. John Ankney





C:\MY DOCUMENTS\ADVA\SCH-13DADIILJA.DOC/ kjs



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission